COMMUNIQUÉS West-GlobeNewswire

SHIRE LAUNCHES MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] IN THE U.S.
05/03/2018
SHIRE LAUNCHES MYPKFIT (TM) FOR ADVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] IN THE U.S. First and only FDA-cleared PK dosing software now available to help healthcare professionals create personalized treatment [...]
Horizon Discovery hosts Capital Markets Day today
05/03/2018
Horizon Discovery Group plc Horizon Discovery hosts Capital Markets Day today Cambridge, UK, 5 March 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a global leader in gene editing and gene [...]
BioDelivery Sciences to Present at the 30th Annual ROTH Conference
05/03/2018
RALEIGH, N.C., March 05, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI ), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that [...]
Lexington Cardiovascular Health Monitor Performing as Designed with First Clinical Patients
05/03/2018
VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to provide an [...]
Medibio signs binding term sheet to acquire Vital Conversations
05/03/2018
Capitalizes on 3 years of partnership success in Corporate Health programs Appoints Peta Slocombe, founder of Australia’s Biggest Mental Health Check-In, to lead Medibio Corporate Health Strategic Business Unit [...]
Ossur Hf : Candidates to the Board of Directors
05/03/2018
Announcement no. 14/2018 Reykjavik, 5 March 2018 Candidates to the Board of Directors Enclosed details on the candidates to the Board of Directors of Össur hf., to be elected at the Company's Annual General Meeting held [...]
Santhera Reports Outcome of Exploratory Trial with Idebenone in PPMS Conducted at the NIH
05/03/2018
Pratteln, Switzerland, March 5, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that the exploratory Phase I/II clinical trial in primary progressive multiple sclerosis (PPMS) conducted as an investigator- [...]
Addex Secures Investor Commitment for CHF40 million Capital Increase Following Successful Completion of Book Building Process
05/03/2018
Geneva, Switzerland, 5 March 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, announced today that the Company has secured investor commitments for [...]
Immutep receives A$686,704 R&D Tax Incentive
05/03/2018
SYDNEY, Australia, March 04, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“Immutep” or the “Company”), is pleased to announce that it has received a A$686,704 cash rebate from the Australian [...]
Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Research (AACR) Epigenetics Conference
04/03/2018
Effect of rigosertib plus azacitidine treatment on epigenetic modulation in cancer cell-lines and patient derived bone marrow cells Study suggests potential novel clinical strategies to improve outcomes for patients [...]
New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for HAE to be Presented at 2018 AAAAI/WAO Joint Congress
03/03/2018
New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for Hereditary Angioedema to be Presented at 2018 AAAAI/WAO Joint Congress - Data from the largest prevention study in HAE [...]
Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02/03/2018
BURLINGTON, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced a grant of inducement stock options to two new employees for an aggregate of 4,000 shares of common stock [...]
Molecular Templates Closes $10 Million Debt Facility with Perceptive Advisors
02/03/2018
AUSTIN, Texas, March 02, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM ) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new [...]
EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update
02/03/2018
WALTHAM, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG ) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and [...]
Clearside Biomedical Schedules Conference Call to Review Topline Results from Pivotal Phase 3 PEACHTREE Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis
02/03/2018
ALPHARETTA, Ga., March 02, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today [...]
Recro Pharma Announces Commercial Team Additions
02/03/2018
MALVERN, Pa., March 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH ), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today [...]
Endocyte Announces Closing of Public Offering of Common Stock
02/03/2018
WEST LAFAYETTE, March 02, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT ), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the closing of an [...]
Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02/03/2018
CHESTERBROOK, Pa., March 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN ) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of February [...]
Sientra® to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, March 13, 2017
02/03/2018
SANTA BARBARA, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN ), a medical aesthetics company (“Sientra or the “Company”), announced today that the Company will release its fourth quarter and [...]

Pages